AVITA Medical, Inc. (RCEL)
After hours:
| Previous close | 8.98 |
| Open | 8.92 |
| Bid | 8.56 x 100 |
| Ask | 8.59 x 100 |
| Day's range | 8.53 - 9.27 |
| 52-week range | 8.46 - 21.70 |
| Volume | |
| Avg. volume | 232,377 |
| Market cap | 220.306M |
| Beta (5Y monthly) | 1.29 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
AVITA Medical to Announce First Quarter 2024 Financial Results
VALENCIA, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that it will report its first quarter 2024 financial results after the close of the U.S. financial markets on Monday, May 13, 2024. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Tuesday, May 14, 2024, at 6:30 a
- GlobeNewswire
AVITA Medical Updates Expected First Quarter 2024 Revenue
VALENCIA, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced an update to its expected commercial revenue for the first quarter of 2024 and reaffirmed expectations for full-year 2024 revenue at the lower end of the previously provided guidance of US$78.5 million to US$84.5 million. For the quarter ended March 31,
- GlobeNewswire
AVITA Medical Submits Response to FDA, Resuming Review Clock for RECELL GO PMA Supplement
VALENCIA, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced it has submitted its response to the U.S. Food and Drug Administration (FDA) for additional information requested in connection to its premarket approval (PMA) supplement for RECELL GO™. This submission resumes the substantive interactive review process u
